267 related articles for article (PubMed ID: 19694364)
1. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
Lehr HA; Schaefer SC; Delaloye JF
Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
3. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
4. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
5. The use of HER2 testing in the management of breast cancer.
Ravdin P
Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
[TBL] [Abstract][Full Text] [Related]
6. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
9. Should HER2 status be routinely measured for all breast cancer patients?
Ravdin PM
Semin Oncol; 1999 Aug; 26(4 Suppl 12):117-23. PubMed ID: 10482203
[TBL] [Abstract][Full Text] [Related]
10. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
12. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
[No Abstract] [Full Text] [Related]
13. Prospect for anti-HER2 receptor therapy in breast cancer.
Brand FX; Ravanel N; Gauchez AS; Pasquier D; Payan R; Fagret D; Mousseau M
Anticancer Res; 2006; 26(1B):463-70. PubMed ID: 16739306
[TBL] [Abstract][Full Text] [Related]
14. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
15. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Pegram M; Slamon D
Semin Oncol; 2000 Oct; 27(5 Suppl 9):13-9. PubMed ID: 11049052
[TBL] [Abstract][Full Text] [Related]
16. Prospect for anti-her2 receptor therapy in breast cancer.
Brand FX; Ravanel N; Gauchez AS; Pasquier D; Payan R; Fagret D; Mousseau M
Anticancer Res; 2006; 26(1B):715-22. PubMed ID: 16739343
[TBL] [Abstract][Full Text] [Related]
17. [Breast cancer and herceptin].
Cornez N; Piccart MJ
Bull Cancer; 2000 Nov; 87(11):847-58. PubMed ID: 11125293
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
19. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
20. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
